Some, like Pfizer Inc. Chief Executive Officer Albert Bourla, were in Washington for the inauguration weekend. And within the corporate ranks, there was optimism that the new administration would ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

In a statement Friday, CEO Stéphane Bancel noted that the company worked to reduce costs by 27% in 2024 compared to 2023. “In 2025, we remain focused on driving sales, delivering up to 10 ...

Moderna (MRNA) reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 4.5% in premarket trading on the earnings results. Moderna reported $966 billion ...

In a statement Friday, CEO Stéphane Bancel noted that the company worked to reduce costs by 27% in 2024 compared to 2023. “In 2025, we remain focused on driving sales, delivering up to 10 product ...

"In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business," CEO Stéphane Bancel said Friday. In ...

Investors have also been watching the company's efforts to prop up its clinical pipeline. In a statement Friday, CEO Stéphane Bancel noted that the company has worked to help reduce costs in in 2024 ...